

Study on collagen type 11A1 and collagen type 4A1 expression in neuroblastoma

Thao Luu Thi Phuong¹, Bao Chi Bui^{2,*}



Use your smartphone to scan this QR code and download this article

ABSTRACT

Objective: Neuroblastoma (NB) is the most common cause of solid cancer-related high death in children. Previous research shows that tumor microenvironment that involved Collagen that plays an important as heterogeneous role in its tumor microenvironment remodeling. However, less study has been described the collagen expression in the NB. Therefore, this study aimed to elucidate the expression of two prominent collagens (COL11A1 and COL4A1) which can be express abnormally in the NB cancer cohort in Vietnam.

Method: We collect the plasma circulating NB tumor cells and biopsies from City Children Hospital HCM city. These samples were operated with droplet digital RT-PCR method to evaluate the mRNA expression of two collagen subtypes: COL11A1 and COL4A1 on five patient biopsies. Internal control is run with GAPDH. Characterisation of clinicopathological traits (such as: age, gender, histology, MYCN amplification and stages) is correlated with the relationship of COL11A1 and COL4A1 mRNA levels.

Results: The results largely confirmed the optimization of COL11A1 and COL4A1 primers and qualified products in droplet digital RT-PCR with internal GAPDH control. In addition, there is a higher COL11A1 mRNA expression in NB than in healthy control. Moreover, higher COL11A1 was significantly linear with high-risk classification (such as stage 3 or 4 comparing versus stage 1 or 2; MYCN amplification versus MYCN no amplification) in this cancer. In contrast, many of the associations between NB and COL4A1 were non-linear. Other clinicopathological traits (such as: age, gender, histology) did not show any significant differences for COL11A1 and COL4A1.

Conclusion: Altogether, this study confirms the COL11A1 could be a potential biomarker to evaluate the prognosis of NB disease. The integration of proteomic and genomic profiling should be added with larger cohort to address the value of COL11A1 in the future.

Key words: Neuroblastoma, collagen, cancer

¹School of Biotechnology, International University, VNUHCM, Vietnam

²School of Medicine, VNUHCM, Vietnam

Correspondence


Bao Chi Bui, School of Medicine, VNUHCM, Vietnam

Email: bcbao@medvnu.edu.vn

History

- Received: 08-6-2021
- Accepted: 08-11-2021
- Published: 26-12-2021

DOI : 10.32508/stdjhs.v2i2.472



Copyright

© VNU-HCM Press. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.



INTRODUCTION

NB is a pediatric tumor originating from neural crest cells¹. It is a heterogeneous characteristic and may contribute by epigenetic regulation during neural differentiation. Despite multiple cancer-related recommendations for treatment, diagnosis, and follow-up, strengthening cancer patients' long-term predictions remains low survival rate². In particular, more than 60% of effective therapy can be operated in developed nations, but only 30% of successful therapy is recorded in developing countries, including Vietnam³. Therefore, it is crucial to find appropriate markers in cancer diagnosis and prognosis.

There are currently at least 28 different collagen proteins that divided into four subtypes based on their super-molecule collection, including fibril-forming collagens, three disrupted helical chains of collagen-binding to fibril, network-forming collagens, and membrane anchor collagens⁴. Type XI collagen is extracellular minor fibrillary collagen, which codes

for the $\alpha 1$ chain of pro-collagen 11A1 and mature COL11A1⁵. COL11A1 levels have also been found to be elevated in many tumor forms, including colorectal, pancreatic, breast, and non-small-cell lung cancer, relative to normal tissues, which can be a target marker for the differential diagnosis of invasive breast carcinoma. COL4A1 encodes the chain of COL4A1 and secretes it into an extracellular matrix⁶. Overregulated COL4A1 facilitates tumor invasion in bladder cancer cells via tumor budding activation⁶. Overexpressed COL4A1 also leads to breast cancer cell proliferation and migration⁷.

To evaluate the two collagens in NB, we examine the different expression levels of COL11A1 and COL4A1 received on NB liquid biopsy. The study focus on assessing the expression of COL11A1 and COL4A1 comparing between NB and healthy donors.

MATERIALS AND METHODS

Cite this article : Phuong T L T, Bui B C. Study on collagen type 11A1 and collagen type 4A1 expression in neuroblastoma. *Sci. Tech. Dev. J. - Health Sci.*; 2(2):289-297.

Sample collection and circulating tumor cell isolation from BP

All samples taken from those diagnosed with NB at City Children's Hospital at Ho Chi Minh City. Ethic reviewer's committee asserts the ethical document at the Ho Chi Minh City Children's Hospital. The peripheral blood sample of healthy control (BL01) was used as a positive control for experimental design of primers (Table 1). Four peripheral blood (PB) samples were NB05, NB06, NB07, NB08 and one tissue sample (NB09) from NB patient. Circulating tumor cells were collected as previously report. In brief, whole PB shipped in 10 mL blood collection tubes (BCT) containing a cell-free RNA preservative. Collect up to 4 mL of plasma from centrifuged and Isolate circulating RNA using a commercially available kit Qiagen that captures exosomes, platelets and cell-free RNA from plasma. Clinical information such as the patient's age, stage of the disease, and MYCN amplification status was provided by the hospitals.

Total RNA extraction

The total RNA will be extracted by using the ThermoFisher Company's GeneJET RNA purification kit. After extraction, total RNA was quantified and qualified using the nanodrop (Thermo Scientific) and gel electrophoresis, respectively. The GeneRuler 100 bp DNA Ladder was used. For tissue, a quantity of around 30 mg per sample was grinded with 1 ml of RMPI. The whole mixture was centrifuged to remove supernatant before 300 μ l of Lysis Buffer (20 μ l of 14.3 M β -mercaptoethanol was applied to each 1 ml amount of Lysis Buffer) and 600 μ l of diluted Proteinase K were added. They were centrifuged for 10 minutes at 12000 g after incubated at room temperature, and then the supernatant was transferred into a new tube. 450 μ l of ethanol (96-100 %) was applied. 700 μ l of lysate was moved into the purification column inserted in a collection tube. Then, they were centrifuged at 12000 g for 1 minute. The flow-through was discarded and the column of purification was inserted back into the collection tube. This process was replicated before all the lysates in the column were transferred. In the purification column, 700 μ l of Wash Buffer 1 and 600 μ l of Wash Buffer 2 was added and centrifuged for 1 minute at 12000 g, respectively. Then, the flow-through was discarded and the column of purification was put back into the collection tube. After, 250 μ l of Wash Buffer 2 was added and centrifuged for 2 minutes at 12000 g. The collection tube was discarded, and a sterile 1.5 mL RNase-free micro-centrifuge tube was transferred to the purification column. Finally, 50 μ l of nuclear-free water

was added to the membrane of the purification column. They were centrifuged at 12000 g to elute RNA for 1 minute. The column was discarded and the purified RNA was used.

For the blood sample, 0.5ml of whole blood was centrifuged at 14000 rpm for 10 minutes. The plasma was removed after centrifugation and the pellet was re-suspended in 600 μ l of Lysis Buffer, adding 20 μ l of 14.3 M β -Mercaptoethanol each 1 ml Lysis Buffer amount. 450 μ l of ethanol (96-100 %) was applied. The remaining steps were performed in the same way as tissue sample.

Semi quantitative RT-PCR

Primer design

Primers are designed using an Origene website (Origene Technologies Inc.). OriGene offers a battery of products for gene expression. The specific primers are checked using Primer blast to perform specificity checking and avoid primer self-complementary.

First-strand cDNA synthesis

The procedure was performed according to the manufacturer's instructions using the Revertaid 1st cDNA Synth Kit of Thermo Scientific. The total RNA was synthesized to cDNA. The total reaction volume was 20 μ l, including primer set 10 pmol, extracted RNA, 5X Reaction Buffer, RiboLock RNase Inhibitor (20 U/ μ L), 10 mM dNTP Mix, RevertAid RT and distilled water. They were mixed gently and centrifuged briefly. Then, they were incubated at 42°C, 60 minutes. The reaction was completed by heating at 70°C for 5 minutes.

Digital droplet RT-PCR

The cDNA was diluted (1:1000) ratio and amplified using the Thermo Scientific DreamTaq Green PCR Master Mix kit on the digital droplet PCR-Qiagen. RT-PCR was set up 2 minutes at 95 for initial denaturation and 30 cycles, each consisting of 30 seconds at 95, 30 seconds at 55, and 1 minute at 72. The close cycle for 10 minutes at 72. GAPDH was used as a control. The PCR ingredients for 1 reaction were 21 μ L of water, nuclease-free, 2 μ L of diluted cDNA, 1 μ L of each primer and 25 μ L of DreamTaq™ Green PCR Master Mix. The total volume of the reaction was 50 μ L reaction. For droplet generation, transfer 20 μ L PCR mix to sample wells on the droplet generation cartridge. Add 70 μ L of droplet generation oil and add droplet generation and then transfer droplets to PCR plate. Aspirate and dispense the droplets slowly,

Table 1: List of primer sequences used for RT-PCR

Name of primer	Sequence 5'-3'	Product length (bp)	Exon position	Tm temperature (°C)
COL11A1-F	ATGGACCAGCAGGATTACGTGG	143	E40	55
COL11A1-R	TGTACCTGCTGACCCACGTTCT		E42	55
COL4A1-F	TGTTGACGGCTTACCTGGAGAC	120	E29	55
COL4A1-R	GGTAGACCAACTCCAGGCTCTC		E30	55
GAPDH-F	AGGTCGGAGTCAACGGATTTG	532		55
GAPDH-R	GTGATGGCATGACTGTGGT			55

*GAPDH: the control was supplied from the Revertaid first cDNA Synth Kit
 F: forward primer, R: reverse primer

over 5 to 6 s each, without touching the opening of the tip to the droplet cartridge.

Amplification products were analyzed by gel electrophoresis. The Gene-Ruler 1 kb Plus DNA Ladder was used. 4 µl of products were separated on 2% gel-containing agarose gel in a 0.5X TBE buffer at 100V in 30 minutes. The PCR results were obtained by using UV Trans-illuminator.

Data analysis

Data visualization and correlation were performed with Prism 8 (Graph-Pad Software Inc). The expression of the phenotype was performed by the t-test. Values expressed as means ± SD and P value <0.05 are statistically significant.

RESULTS

Quantitative and qualitative results of the total RNA collected from samples

The total RNA was quantitated by using the nanodrop (Thermo Scientific). Finally, total RNA products were checked by using gel electrophoresis.

The concentration was the highest in the NB09 specimen (132.16 ng/µl). The concentration of blood samples, by comparison, was lower. Four samples of blood under 60 ng/µl were obtained, the lowest total RNA concentration was recorded in sample NB07. The 260/280 ratio (approximately 2) indicates pure RNA (Table 2).

All gDNA bands appear in the above of well. We can see 2 clear bands of 28S and 18S rRNA in lanes of BL01, NB06 and NB09 samples. In lanes of NB05 and NB08, there was no presence of the 18s band. In lane NB07, there were no both 18S and 28S of rRNA (Figure 1). The theoretical 28S:18S ratio was around 2:1, and this ratio suggests the intact RNA. However, further research was required to see whether there was a relationship between the amount of RNA profiles and mRNA integrity.

The optimal GAPDH within blood and tissue samples

Optimization of the GAPDH is important for internal control and is quantitative to COL11A1 and COL4A1 level. The product of mRNA was shown the best at 55°C. which illustrated in Figure 2.

Both BL01 and control had the expression of GAPDH at appropriate band of 532 bp. Particularly, the BL01 was much lower than that of the healthy control (Figure 3). Moreover, the results in Figure 4 showed that GAPDH expressed in both blood and tissue samples. The length of the products was 532 bp.

Optimization of amplification products of COL4A1 and COL11A1 with blood and NB samples

The gel electrophoresis result from Figure 4 showed the successful PCR product amplification reaction. Specifically, the appearance of products at 120bp and 140bp, respectively. There was no discernible change in most samples in most samples in COL4A1 expression, except where no expression was observed in the tissue sample. However, the COL11A1 gene showed a significant difference between the patients diagnosed with NB compared with the normal control.

Testing the expression of the COL11A1 and COL4A1 on NB samples

The mRNA levels normalized to GAPDH of COL4A1 and COL11A1 were significant differences (P<0.05) between each group (Figure 5A). Comparing with the stage I-II, there was a significant difference in the expression of COL4A1 and COL11A1 (P<0.05). MYCN non-amplification status has a significant difference between COL4A1 and COL11A1 (P<0.01). No significant difference was found in Stage III-IV and MYCN amplification (Figure 5A). There were no significant differences in the expression of COL4A1 and COL11A1 in the early stage compared to the later

Table 2: The quality of the total RNA for first-strand cDNA synthesis

No.	Code	Concentration (ng/ μ l)	260/280 ratio	260/230 ratio
1	BL01	78	2.25	1.83
2	NB05	36.28	2.02	1.84
3	NB06	55,00	2.20	2.04
4	NB07	32.51	2.10	1.72
5	NB08	34.88	2.18	1.67
6	NB09	132.16	2.19	1.87




Figure 1: Visualization of total RNA product by gel electrophoresis

stage. The opposite is true for the MYCN amplification (Figure 5B).

Correlation of collagen expression with NB clinic pathological parameter

COL11A1 expressed positive in all samples of patients diagnosed with NB at both early (stage 2) and later stages (stage 3) and not expressed in the normal human sample, indicating that this gene may help diagnose NB. There was a difference in the expression of COL4A1 in tissue compared to blood samples in this experiment. Depending on whether MYCN amplification is present or not, the patients were divided into MYCN amplification (n=1) and non-MYCN amplification (n=5). The expression of mRNA was compared between the two groups to obtain differentially COL4A1 expressed gene (Table 3).

DISCUSSION

NB cases under 18 months of age were not operated on, and the obtained samples were over 18 months old. Therefore, age-based gene expression could not be compared to the International NB Staging System Committee (INSS).

The mRNA expression of COL11A1 was significantly higher in NB samples than in the non-patient sample in this experiment, but COL4A1 mRNA expression did not differ significantly between patient samples and normal samples. In colorectal cancer tissue, COL11A1 mRNA expression was slightly higher than in normal colonic tissue⁸. Studies in non-small cell lung cancer⁹ and breast cancer¹⁰, pancreatic cancer¹¹ have also demonstrated increased levels of COL11A1 in tumor tissue compared with normal tissue. COL11A1 has been related to cancer cell growth and tumorigenesis in recent studies. Compared to matched neighboring non-tumor gastric tis-




Figure 2: The GAPDH amplification at control RNA and BL01 samples. *A: The cDNA was diluted (1:1000); B: The cDNA was diluted (2:1000); C: The cDNA was diluted (3:1000)

Table 3: Clinical diagnosis and the gene expression result of COL4A1 and COL11A1

Code	Type	Age (month)	Stage	MYCN amplify	Non-MYCN amplify	The expression of COL4A1	The expression of COL11A1
NB05	Blood	21	2		X	+	+
NB06	Blood	29	2		X	+	+
NB07	Blood	76	3		X	+	+
NB08	Blood	98	3		X	+	+
NB09	Tissue	85	3	X		-	+

*+: positive; -: negative




Figure 3: The GAPDH amplification at NB samples




Figure 4: Blood and NB samples are examined by two different primer sets towards COL4A1(A) or COL11A1(B) expressions




Figure 5: Violin box plot of mRNA levels that normalized to GAPDH. (A). Comparison between COL11A1 and COL4A1; (B). Comparison between stages and MYCN amplification status

sue, COL11A1 mRNA expression was substantially overexpressed in gastric cancer tissues. Age, tumor invasion depth, tumor duration, and lymph node positivity were all found to be strongly positively linked to COL11A1 mRNA expression. The advanced GC had slightly higher COL11A1 mRNA expression than the early GC¹². More study is required to identify the mechanisms by which COL11A1 influences the behavior of cancer cells. COL4A1 has also been extensively studied for its effects in various types of cancer. Overregulated COL4A1 facilitates tumor invasion in bladder cancer cells via tumor budding activation¹³. Overexpressed COL4A1 leads to breast cancer cell proliferation and migration¹⁴. A couple of previous reports demonstrated that COL4A1 acts as a promoter of angiogenesis and tumor progression. Of all the patients diagnosed with this NB by a doctor, patient NB09 underwent was surgically removed. Currently, the patient is still being monitored and so far, no symptoms have been reported from the doctors at the Ho Chi Minh City Children’s Hospital. Finally, based on the number of patients with NB, the patient’s health condition, and the doctor’s treatment at the Ho Chi Minh City Children’s Hospital, it was difficult to determine samples during the collection of results. Therefore, it could not perform this study with large cohorts. In addition, RNA is easily degraded down during transport and storage, so a more rigorous procedure is needed to limit the breakdown of RNA.

This research is a primary test in detecting molecular diagnostic NB patients in the Ho Chi Minh city children’s hospital. COL11A1 and COL4A1 can serve as an indicator for expanding the samples study.

CONCLUSION

This study indicated that the gene expression of COL11A1 in patients was higher than that of healthy people. Moreover, COL11A1 expressed positively in all samples of patients diagnosed with NB. Thus, the experiments provided apparent data for the contribution to NB diagnosis. However, the COL4A1 gene expression did not show a significant difference between normal people and those with NB.

The research of COL11A1 amplify the significant phase in the clinical management of NB since it is beneficial for patients with NB to select for treatment at an early stage and ensures the best result for patients.

ACKNOWLEDGEMENTS

We would like to thank the grant from Vietnam National University Ho Chi Minh grant #CC02021-44-03.

ETHICAL COMPLIANCE

The study protocol was approved by the Review Board committee of City Children’s Hospital (CS/NTP/20/13). The study was conducted in accordance with the Good Clinical Practice and the Declaration of Helsinki. All parents of the child patients provided informed consents prior to study.

FUNDING

The study is mainly supported by the Vietnam National University Ho Chi Minh city grant (#CC2021-44-03).

CONFLICTS OF INTEREST

The authors declare no conflict of interest.

AUTHORS' CONTRIBUTIONS

Bao Chi Bui (CB) and Thao Luu Thi Phuong (TP) designed and wrote the manuscript. CB, and TP were involved in the peer review. TP worked on the molecular studies and their interpretation. CB reviewed the manuscript critically. All authors read and approved the final manuscript.

REFERENCES

1. Ackermann S, Cartolano M, Hero B, Welte A, Kahlert Y, Roderwieser A, et al. A mechanistic classification of clinical phenotypes in neuroblastoma. *Science*. 2018;362(6419):1165;PMID: 30523111. Available from: <https://doi.org/10.1126/science.aat6768>.
2. Matthey KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, et al. Neuroblastoma. *Nature Reviews Disease Primers*. 2016;2;PMID: 27830764. Available from: <https://doi.org/10.1038/nrdp.2016.78>.
3. Bui C-B, Nguyen UH, Truong DK, Vo NV, Vu D-M, Nguyen UD, et al. Neuroblastoma in Vietnam: A retrospective analysis of MYCN status and clinical features to inform prognosis and improve outcome. *Pediatr Dimensions*. 2019;4; Available from: <https://doi.org/10.15761/PD.1000195>.
4. Ida T, Kaku M, Kitami M, Terajima M, Rosales Rocabado JM, Akiba Y, et al. Extracellular matrix with defective collagen cross-linking affects the differentiation of bone cells. *PLOS ONE*. 2018;13(9):e0204306;PMID: 30252876. Available from: <https://doi.org/10.1371/journal.pone.0204306>.
5. Wu YH, Chang TH, Huang YF, Huang HD, Chou CY. COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer. *Oncogene*. 2014;33(26):3432-40;PMID: 23934190. Available from: <https://doi.org/10.1038/onc.2013.307>.
6. Miyake M, Hori S, Morizawa Y, Tatsumi Y, Toritsuka M, Ohnishi S, et al. Collagen type IV alpha 1 (COL4A1) and collagen type XIII alpha 1 (COL13A1) produced in cancer cells promote tumor budding at the invasion front in human urothelial carcinoma of the bladder. *Oncotarget*. 2017;8(22):36099-114;PMID: 28415608. Available from: <https://doi.org/10.18632/oncotarget.16432>.
7. Li A, Li J, Lin J, Zhuo W, Si J. COL11A1 is overexpressed in gastric cancer tissues and regulates proliferation, migration and invasion of HGC-27 gastric cancer cells in vitro. *Oncol Rep*. 2017;37(1):333-40;PMID: 28004111. Available from: <https://doi.org/10.3892/or.2016.5276>.
8. Duan XF, Zhao Q. TERT-mediated and ATRX-mediated Telomere Maintenance and Neuroblastoma. *J Pediatr Hematol Oncol*. 2018;40(1):1-6;PMID: 28452859. Available from: <https://doi.org/10.1097/MPH.0000000000000840>.
9. Hellmann MD, Nathanson T, Rizvi H, Creelan BC, Sanchez-Vega F, Ahuja A, et al. Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. *Cancer Cell*. 2018;33(5):843-52.e4;PMID: 29657128. Available from: <https://doi.org/10.1016/j.ccell.2018.03.018>.
10. Takao C, Morikawa A, Ohkubo H, Kito Y, Saigo C, Sakuratani T, et al. Downregulation of ARID1A, a component of the SWI/SNF chromatin remodeling complex, in breast cancer. *J Cancer*. 2017;8(1):1-8;PMID: 28123592. Available from: <https://doi.org/10.7150/jca.16602>.
11. Tanaka N, Yamada S, Sonohara F, Suenaga M, Hayashi M, Takami H, et al. Clinical Implications of Lysyl Oxidase-Like Protein 2 Expression in Pancreatic Cancer. *Scientific Reports*. 2018;8(1):9846;PMID: 29959362. Available from: <https://doi.org/10.1038/s41598-018-28253-9>.
12. Fernandez-Torres J, Martinez-Nava GA, Zamudio-Cuevas Y, Martinez-Flores K, Mijares-Diaz F. Multifactor dimensionality reduction reveals a strong gene-gene interaction between STC1 and COL11A1 genes as a possible risk factor of knee osteoarthritis. *Mol Biol Rep*. 2020;47(4):2627-34;PMID: 32140959. Available from: <https://doi.org/10.1007/s11033-020-05351-4>.
13. Baghdadi MB, Castel D, Machado L, Fukada S-i, Birk DE, Relaix F, et al. Reciprocal signalling by Notch-Collagen V-CALCR retains muscle stem cells in their niche. *Nature*. 2018;557(7707):714-8;PMID: 29795344. Available from: <https://doi.org/10.1038/s41586-018-0144-9>.
14. Tadeo I, Berbegall AP, Navarro S, Castel V, Noguera R. A stiff extracellular matrix is associated with malignancy in peripheral neuroblastic tumors. *Pediatr Blood Cancer*. 2017;PMID: 28121069. Available from: <https://doi.org/10.1002/pbc.26449>.

Nghiên cứu về sự biểu hiện của loại collagen 11A1 và collagen 4A trong u nguyên bào thần kinh

Lưu Thị Phương Thảo¹, Bùi Chí Bảo^{2,*}



Use your smartphone to scan this QR code and download this article

TÓM TẮT

Mục tiêu: U nguyên bào thần kinh (UNBTK) là nguyên nhân phổ biến nhất gây tử vong cao liên quan đến ung thư ở trẻ em. Nghiên cứu trước đây cho thấy vi môi trường khối u liên quan đến Collagen đóng vai trò quan trọng trong quá trình tái cấu trúc vi môi trường khối u. Tuy nhiên, ít nghiên cứu được mô tả về biểu hiện collagen nào đặc trưng trong UNKBT. Vì vậy, nghiên cứu này nhằm làm rõ sự biểu hiện của hai collagens nổi bật (COL11A1 và COL4A1) có thể biểu hiện bất thường như thế nào trong nhóm ung thư UNKBT ở Việt Nam.

Phương pháp: Chúng tôi thu thập tế bào khối u UNKBT lưu hành trong huyết tương và sinh thiết từ Bệnh viện Nhi Đồng TP.HCM. Các mẫu này được phẫu thuật bằng phương pháp kỹ thuật số dạng giọt RT-PCR để đánh giá biểu hiện mRNA của hai phân nhóm collagen: COL11A1 và COL4A1 trên năm mẫu sinh thiết của bệnh nhân. Kiểm soát nội bộ được chạy với mỗi GAPDH. Đặc điểm của các đặc điểm bệnh lý lâm sàng (chẳng hạn như: tuổi, giới tính, mô học, khuếch đại MYCN và các giai đoạn) liệu có tương quan với mối quan hệ của nồng độ mRNA COL11A1 và COL4A1.

Kết quả: Kết quả phần lớn khẳng định tính tối ưu của mỗi COL11A1 và COL4A1 và các sản phẩm đủ tiêu chuẩn trong kỹ thuật số dạng giọt RT-PCR với kiểm soát GAPDH nội bộ. Ngoài ra, có biểu hiện mRNA COL11A1 ở NB cao hơn so với đối chứng khỏe mạnh. Hơn nữa, COL11A1 cao hơn có ý nghĩa tuyến tính với phân loại nguy cơ cao (chẳng hạn như giai đoạn 3 hoặc 4 so sánh với giai đoạn 1 hoặc 2; MYCN khuếch đại so với MYCN không khuếch đại) trong bệnh ung thư này. Ngược lại, nhiều mối liên hệ giữa UNBTK và COL4A1 là phi tuyến tính. Các đặc điểm bệnh lý lâm sàng khác (như: tuổi, giới tính, mô học) không cho thấy bất kỳ sự khác biệt đáng kể nào đối với COL11A1 và COL4A1.

Kết luận: Nhìn chung, nghiên cứu này khẳng định COL11A1 có thể là một dấu ấn sinh học tiềm năng để đánh giá tiên lượng của bệnh NB. Việc tích hợp cấu hình hệ protein và hệ gen nên được bổ sung với nhóm thuần tập lớn hơn để giải quyết giá trị của COL11A1 trong nghiên cứu tương lai.

Từ khóa: U nguyên bào thần kinh, collagen, ung thư

¹Khoa Công nghệ Sinh học, Đại học Quốc tế, ĐHQG-HCM, Việt Nam

²Khoa Y, ĐHQG-HCM, Việt Nam

Liên hệ


Bùi Chí Bảo, Khoa Y, ĐHQG-HCM, Việt Nam

Email: bcbao@medvnu.edu.vn

Lịch sử

- Ngày nhận: 08-6-2021
- Ngày chấp nhận: 08-11-2021
- Ngày đăng: 26-12-2021

DOI: 10.32508/stdjhs.v2i2.472



Bản quyền

© ĐHQG Tp.HCM. Đây là bài báo công bố mở được phát hành theo các điều khoản của the Creative Commons Attribution 4.0 International license.



Trích dẫn bài báo này: Thảo L T P, Bảo B C. **Nghiên cứu về sự biểu hiện của loại collagen 11A1 và collagen 4A trong u nguyên bào thần kinh.** *Sci. Tech. Dev. J. - Health Sci.*; 2(2):289-297.